Heiner Haug is a researcher in economics at the University of Paris 1(Sorbonne), where he joined the PRISM research unit in 2004. His main interests lie in the economic and strategic dimensions of competition between brand name drugs and generic drugs. Ongoing research projects concentrate on demand behaviour and market structure in post-patent markets for prescription drugs, as well as on pharmaceutical companies’ strategic behaviour and related antitrust issues. Heiner holds a doctorate in economics from Sorbonne University. He graduated from the ESCP-EAP European School of Management in Paris in 2003, after studying in Germany, the UK, Spain and France.
8585
Since the beginning of 2006, the economic and legal war between laboratories and generics companies has seen new developments, which lead us to update our study published in issue 1-2006 of this journal. We will focus our attention on two types of behavior that have recently come to the (...)
14115
Facing patent expiry and competition from generic drugs, pharmaceutical companies rely on a wide array of defensive strategies, building on the innovator’s brand image, the extension of the legal market exclusivity period, or the launch of second generation products. While all of these (...)
